

## Publications 2006

---

Al Najjar, A., I. Etienne, P. Le Pogamp, F. Bridoux, Y. Le Meur, O. Toupance, C. Mousson, S. Caillard, B. H. de Ligny, J. F. Marliere, and Y. Lebranchu. 2006. Long-term results of monoclonal anti-il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. *Transplant Proc* 38:2298.

Buchler, M., A. Bretagnol, C. Desaldeleer, P. Garreau, J. M. Halimi, A. Al-Najjar, J. F. Marliere, H. Nivet, and Y. Lebranchu. 2006. Estimation of the glomerular filtration rate through different methods in kidney transplant recipients: correlation with the creatinine clearance measurement. *Transplant Proc* 38:2289.

Buchler, M., S. Chadban, E. Cole, K. Midtvedt, E. Thervet, H. Prestele, and P. Keown. 2006. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases. *Nephrol Dial Transplant* 21:197;

Chapman, J., A. Bock, B. Dussol, L. Fritsche, V. Kliem, Y. Lebranchu, F. Oppenheimer, E. Pohanka, M. Salvadori, and G. Tufveson. 2006. Follow-up after renal transplantation with organs from donors after cardiac death. *Transpl Int* 19:715;

Choquet, S., V. Leblond, R. Herbrecht, G. Socie, A. M. Stoppa, P. Vandenberghe, A. Fischer, F. Morschhauser, G. Salles, W. Feremans, E. Vilmer, M. N. Peraldi, P. Lang, Y. Lebranchu, E. Oksenhendler, J. L. Garnier, T. Lamy, A. Jaccard, A. Ferrant, F. Offner, O. Hermine, A. Moreau, S. Fafi-Kremer, P. Morand, L. Chatenoud, N. Berriot-Varoqueaux, L. Bergougnot, and N. Milpied. 2006. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. *Blood* 107:3053;

Halimi, J., I. Laouad, M. Buchler, A. Al-Najjar, V. Chatelet, T. S. Houssaini, H. Nivet, and Y. Lebranchu. 2006. Early Proteinuria Is a Strong Indicator of Donor Renal Lesions, Ischemia-Reperfusion Injury and Immunological Aggression. *Transplant Proc* 38:2319.

Halimi, J. M., A. Al-Najjar, M. Buchler, and I. Laouad. 2006. Nephron dosing and proteinuria. *Am J Transplant* 6:1495; Salvadori, M., A. Rosati, E. Bertoni, A. Bock, J. Chapman, B. Dussol, L. Fritsche, V. Kliem, Y. Lebranchu, F. Oppenheimer, E. Pohanka, G. Tufveson, and M. Soergel. 2006. Low 1-year cyclosporine microemulsion doses are associated with better 5-year renal graft function: an insight from MOST, a multinational observational study. *Transplant Proc* 38:1010;

Salvadori, M., A. Rosati, A. Bock, J. Chapman, B. Dussol, L. Fritsche, V. Kliem, Y. Lebranchu, F. Oppenheimer, E. Pohanka, G. Tufveson, and E. Bertoni. 2006. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. *Transplantation* 81:202;

Vargas-Poussou, R., P. Houillier, N. Le Pottier, L. Strompf, C. Loirat, V. Baudouin, M. A. Macher, M. Dechaux, T. Ulinski, F. Nobili, P. Eckart, R. Novo, M. Cailliez, R. Salomon, H. Nivet, P. Cochat, I. Tack, A. Fargeot, F. Bouissou, G. R. Kesler, S. Lorotte, N. Godefroid, V. Layet, G. Morin, X. Jeunemaitre, and A. Blanchard. 2006. Genetic investigation of autosomal recessive distal renal tubular acidosis: evidence for early sensorineural hearing loss associated with mutations in the ATP6V0A4 gene. *J Am Soc Nephrol* 17:1437;

Hoarau, C., C. Lagaraine, L. Martin, F. Velge-Roussel, and Y. Lebranchu. 2006. Supernatant of *Bifidobacterium breve* induces dendritic cell maturation, activation, and survival through a Toll-like receptor 2 pathway. *J Allergy Clin Immunol* 117:696;